Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline

The anti-tuberculosis therapeutic bedaquiline (BDQ) is used against Mycobacterium abscessus. In M. abscessus BDQ is only bacteriostatic and less potent compared to M.tuberculosis or M. smegmatis. Here we demonstrate its reduced ATP synthesis inhibition against M. abscessus inside-out vesicles, inclu...

Full description

Saved in:
Bibliographic Details
Main Authors: Krah, Alexander, Ragunathan, Priya, Bond, Peter J., Grüber, Gerhard
Other Authors: School of Biological Sciences
Format: Article
Language:English
Published: 2023
Subjects:
Online Access:https://hdl.handle.net/10356/172413
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-172413
record_format dspace
spelling sg-ntu-dr.10356-1724132024-01-11T00:53:49Z Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline Krah, Alexander Ragunathan, Priya Bond, Peter J. Grüber, Gerhard School of Biological Sciences Science::Biological sciences::Biochemistry Mycobacterium Abscessus Nontuberculous Mycobacteria Bioenergetics F-ATP Synthase Multi Drug Resistance Molecular Dynamics Simulations Diarylquinolines The anti-tuberculosis therapeutic bedaquiline (BDQ) is used against Mycobacterium abscessus. In M. abscessus BDQ is only bacteriostatic and less potent compared to M.tuberculosis or M. smegmatis. Here we demonstrate its reduced ATP synthesis inhibition against M. abscessus inside-out vesicles, including the F1FO-ATP synthase. Molecular dynamics simulations and binding free energy calculations highlight the differences in drug- binding of the M. abscessus and M. smegmatis FO-domain at the lagging site, where the drug deploys its mechanistic action, inhibiting ATP synthesis. These data pave the way for improved anti-M. abscessus BDQ analogs. National Research Foundation (NRF) Submitted/Accepted version This work was supported by the National Research Foundation (NRF) Singapore, NRF Competitive Research Programme (CRP), Grant Award Number NRF: NRF- CRP27-2021-0002(G.G.) and by BII core funds (A.K.and P.J.B.). 2023-12-12T06:36:12Z 2023-12-12T06:36:12Z 2023 Journal Article Krah, A., Ragunathan, P., Bond, P. J. & Grüber, G. (2023). Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline. Biochemical and Biophysical Research Communications, 690, 149249-. https://dx.doi.org/10.1016/j.bbrc.2023.149249. 0006-291X https://hdl.handle.net/10356/172413 10.1016/j.bbrc.2023.149249. 690 149249 en NRF-CRP27-2021-0002 Biochemical and Biophysical Research Communications © 2023 Elsevier Inc. All rights reserved. This article may be downloaded for personal use only. Any other use requires prior permission of the copyright holder. The Version of Record is available online at http://doi.org/10.1016/j.bbrc.2023.149249. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Biological sciences::Biochemistry
Mycobacterium Abscessus
Nontuberculous Mycobacteria
Bioenergetics
F-ATP Synthase
Multi Drug Resistance
Molecular Dynamics Simulations
Diarylquinolines
spellingShingle Science::Biological sciences::Biochemistry
Mycobacterium Abscessus
Nontuberculous Mycobacteria
Bioenergetics
F-ATP Synthase
Multi Drug Resistance
Molecular Dynamics Simulations
Diarylquinolines
Krah, Alexander
Ragunathan, Priya
Bond, Peter J.
Grüber, Gerhard
Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline
description The anti-tuberculosis therapeutic bedaquiline (BDQ) is used against Mycobacterium abscessus. In M. abscessus BDQ is only bacteriostatic and less potent compared to M.tuberculosis or M. smegmatis. Here we demonstrate its reduced ATP synthesis inhibition against M. abscessus inside-out vesicles, including the F1FO-ATP synthase. Molecular dynamics simulations and binding free energy calculations highlight the differences in drug- binding of the M. abscessus and M. smegmatis FO-domain at the lagging site, where the drug deploys its mechanistic action, inhibiting ATP synthesis. These data pave the way for improved anti-M. abscessus BDQ analogs.
author2 School of Biological Sciences
author_facet School of Biological Sciences
Krah, Alexander
Ragunathan, Priya
Bond, Peter J.
Grüber, Gerhard
format Article
author Krah, Alexander
Ragunathan, Priya
Bond, Peter J.
Grüber, Gerhard
author_sort Krah, Alexander
title Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline
title_short Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline
title_full Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline
title_fullStr Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline
title_full_unstemmed Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline
title_sort variations of the mycobacterium abscessus f-atp synthase subunit a-c interface alter binding and potency of the anti-tb drug bedaquiline
publishDate 2023
url https://hdl.handle.net/10356/172413
_version_ 1789482870886105088